Associations of glucose- and lipid-lowering medications with incident or first-recorded psoriasis: a systematic review of real-world observational studies.

What was studied

This review asked if blood sugar and blood fat drugs are linked to new psoriasis. It used 18 reports from real-world observational studies. The team searched up to 1 July 2026 and updated on 11 September 2026. Results were summarized in words, not pooled. The reason was a lack of comparable estimates.

What they found

Estimates for dipeptidyl peptidase-4 drugs were generally below 1. Results for GLP-1 drugs depended on the comparison drug. Most SGLT2 drug estimates sat near the null or above it. Metformin and thiazolidinediones gave lower estimates in some studies. Statins showed no steady link. Of 18 reports, 13 had serious bias risk, and none had low risk.

What it means for patients

The authors say the evidence does not show these drugs cause or prevent psoriasis. They say it does not support choosing or avoiding them just to prevent psoriasis.

Why it is not certain yet

The findings are only ideas to test. Confounding by indication and other bias risks limit them. Several reports may have used overlapping groups of people. Independent evidence was limited.

Source

Associations of glucose- and lipid-lowering medications with incident or first-recorded psoriasis: a systematic review of real-world observational studies.

We restate facts from the source record in our own words. The original wording belongs to its publisher.